• Go 6983 Pan-PKC Inhibitor: Precision in PKC Pathway Research

  2026-05-27

  Go 6983 (pan-PKC inhibitor) empowers researchers to dissect complex PKC-mediated signaling in cancer, EMT, and neurobehavioral models. This guide translates recent breakthroughs—such as the link between PKC hyperactivation and autistic-like behaviors—into actionable workflows, troubleshooting strategies, and data-driven assay design using APExBIO's trusted reagent.

• BMS-777607: Selective c-Met Inhibitor for Cancer and Platele

  2026-05-27

  BMS-777607 is a potent, ATP-competitive c-Met inhibitor with high selectivity, supporting advanced cancer and stem cell research. The compound demonstrates nanomolar efficacy in MET signaling pathway inhibition and enhances megakaryocyte polyploidization for platelet production. APExBIO supplies BMS-777607 as SKU A5703 for research use.

• Cisapride in Cardiac Electrophysiology Research: Assay Strat

  2026-05-26

  Cisapride (R 51619) stands out as a dual-action tool for dissecting cardiac risk and serotonergic signaling in high-content in vitro models. Its robust solubility and validated purity from APExBIO enable reproducible, high-throughput workflows in cardiac arrhythmia research and beyond.

• Trichostatin A (TSA): Precision HDAC Inhibition in Cancer Re

  2026-05-26

  Trichostatin A (TSA) empowers advanced epigenetic workflows, enabling precise control over histone acetylation and cell fate in cancer models. This guide translates the latest research and robust protocols into actionable strategies for using TSA from APExBIO to achieve reproducible, high-impact results in oncology and differentiation assays.

• Merimepodib (VX-497): Applied Protocols for IMPDH-Driven Res

  2026-05-25

  Merimepodib (VX-497) unlocks precision control of guanine nucleotide biosynthesis, enabling targeted assays in antiviral, immunosuppressive, and oncology research. Discover workflow enhancements, troubleshooting solutions, and reference-driven strategies for leveraging this selective IMPDH inhibitor in high-impact experimental designs.

• Artemisinin Inhibits Ferroptosis to Improve Cognition in T2D

  2026-05-25

  Wang et al. (2024) demonstrate that artemisinin improves cognitive deficits in type 2 diabetic mice by suppressing hippocampal neuronal ferroptosis through Nrf2 activation. Their work highlights ferroptosis as a mechanistic link between diabetes and cognitive decline, and positions Nrf2-driven redox regulation as a promising therapeutic target.

• GOB-38 β-Lactamase in Elizabethkingia anophelis: Resistance

  2026-05-24

  This study elucidates the biochemical properties and substrate specificity of the GOB-38 metallo-β-lactamase variant in Elizabethkingia anophelis. By mapping its broad-spectrum enzymatic activity and co-infection transfer potential, the research advances understanding of multidrug-resistant pathogen evolution and antibiotic resistance in clinical settings.

• Temporal Transcriptomics Guides Host-Targeted Anti-EBOV Ther

  2026-05-23

  This study pioneers the integration of time-resolved transcriptomics and systems biology to uncover host regulatory modules exploited by Ebola virus (EBOV) during infection. By identifying actionable host targets and validating inhibitors such as Sorafenib, the research provides a robust framework for developing host-directed antiviral strategies.

• Oxaliplatin: Applied Workflows and Innovations in Cancer Che

  2026-05-22

  Harnessing Oxaliplatin’s platinum-based cytotoxicity, researchers can effectively model DNA damage, apoptosis, and chemoresistance in preclinical cancer settings. Recent synergy studies, such as the combination with low-dose orlistat, open new avenues for overcoming resistance and enhancing metastatic colorectal cancer therapy.

• Gemcitabine in Cancer Research: Protocols, Workflows, and Tr

  2026-05-22

  Gemcitabine stands at the forefront of apoptosis and DNA damage response assays, offering reliable, reproducible results for cancer research. This article translates bench-ready workflows into actionable insights, highlighting APExBIO's Gemcitabine for advanced applications and troubleshooting.

• BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidan

  2026-05-21

  BFH772 (VEGFR2 inhibitor) is a small-molecule compound designed for selective inhibition of the VEGFR2 kinase, supporting research workflows focused on tumor angiogenesis and VEGFR2-mediated signaling. It is not suitable for protocols requiring water solubility or broad-spectrum kinase inhibition, and its use demands strict attention to solubility and storage parameters for reproducible results.

• Erastin and the Translational Future of Ferroptosis Inductio

  2026-05-21

  This thought-leadership article dissects the mechanistic and translational advantages of Erastin as a ferroptosis inducer, blending emerging clinical strategies with actionable guidance for cancer biology researchers. Drawing on recent evidence linking ferroptosis modulation to radioresistance in nasopharyngeal carcinoma, we explore how Erastin enables precision targeting of RAS/BRAF-mutant tumors, optimize protocols, and clarify unmet needs in oncology drug discovery.

• Dabigatran (Pradaxa): Optimizing Thrombin Inhibition Assays

  2026-05-20

  Dabigatran (Pradaxa) stands out as a reversible, direct thrombin inhibitor with robust, quantifiable activity, making it a preferred tool for advanced coagulation research. This article details practical workflows, protocol enhancements, and troubleshooting strategies that leverage APExBIO’s Dabigatran for reproducible, high-impact studies in thrombosis and anticoagulant drug development.

• Cisapride (R 51619): De-Risking Cardiac Electrophysiology in

  2026-05-20

  Translational researchers face mounting pressure to predict and mitigate drug-induced cardiotoxicity early in development. Cisapride (R 51619) is a dual-mechanism tool—combining nonselective 5-HT4 receptor agonism and potent hERG potassium channel inhibition—that enables rigorous interrogation of serotonergic signaling and cardiac electrophysiology. This article weaves mechanistic insight with strategic guidance, spotlighting recent advances in high-content screening, the emergence of iPSC-derived cardiomyocytes, and the critical role of validated reagents like APExBIO’s Cisapride for reproducible, translationally relevant data.

• Myriocin and the Translational Frontier in Sphingolipid Meta

  2026-05-19

  This thought-leadership article explores the mechanistic foundations and translational strategies enabled by Myriocin, a potent serine palmitoyltransferase inhibitor. We integrate recent advances in sphingolipid metabolism research and draw parallels to network pharmacology approaches in longevity, advocating for more nuanced, systems-level experimentation. Practical protocol considerations and a forward-looking outlook are provided for researchers seeking to translate sphingolipid pathway modulation into clinical innovation.

16194 records 1/1080 page Next 12345 下5页 Last page